Physician profile

Kenneth Otah

Interventional Cardiology · Sugar Land, TX

NPI 1093704827

$8,280.50

in general payments reported to CMS, 2019-2025

45 companies · $441 in 2025

The $441 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,865.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $2,300.69 2019
Astrazeneca Pharmaceuticals LP $1,017.99 2020-2025 Farxiga, Wainua
Cardiovascular Systems INC. $595.88 2019-2021
Merck Sharp & Dohme LLC $553.23 2022-2025 Verquvo, Capvaxive
Janssen Pharmaceuticals, INC $528.21 2019-2024 Xarelto
Sanofi-Aventis U.S. LLC $494.65 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $363.23 2019-2024 Lifevest
Philips North America LLC $263.73 2019-2023
Boston Scientific Corporation $231.41 2021-2025 Lux-Dx Insertable Cardiac Monitor, Bodyguardian
Pfizer INC. $172.05 2020-2022
Intuitive Surgical, INC. $171.32 2019-2021
Medtronic Vascular, INC. $163.11 2019-2020
Angiodynamics, INC. $160.63 2020-2022
Novartis Pharmaceuticals Corporation $106.95 2019-2024
Amgen INC. $90.27 2023-2025 Repatha, Repatha
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Terumo Medical Corporation $87.60 2019
Redhill Biopharma INC. $87.29 2020-2021
Alnylam Pharmaceuticals INC. $78.65 2021-2023 Onpattro
Cordis US Corp. $77.11 2022
E.R. Squibb & Sons, L.L.C. $62.10 2024-2025 Eliquis, Camzyos
Kiniksa Pharmaceuticals International, Plc $58.96 2024 Arcalyst
Kci USA, INC. $53.35 2021
Boehringer Ingelheim Pharmaceuticals, INC. $52.33 2021-2024 Jardiance
Integra Lifesciences Corporation $48.15 2022-2025 Neuragen
Edwards Lifesciences Corporation $43.54 2023 Sapien 3 Ultra Resilia
Medtronic, INC. $36.21 2021
Biotronik INC. $31.82 2023 Pantera Leo, Pk Papyrus, Orsiro Mission
Acera Surgical, INC. $28.11 2025 Restrata Wound Matrix
Baxter Healthcare $26.59 2024 Hillrom - Carnation Ambulatory Monitor
Smith+Nephew, INC. $26.09 2019-2020
Mimedx Group, INC. $24.38 2024
Esperion Therapeutics, INC. $24.12 2020
Davol INC. $23.58 2019
Lexicon Pharmaceuticals, INC. $22.73 2024
Kowa Pharmaceuticals America, INC. $21.30 2021
Genzyme Corporation $19.19 2021
Takeda Pharmaceuticals U.S.A., INC. $18.82 2023 Gattex
Medline Industries LP $16.59 2022
Acell, INC. $16.17 2019
Ossur Americas, INC. $15.67 2025
Heartflow, INC. $15.39 2023 Ffrct
Endo Pharmaceuticals INC. $13.71 2022
Ethicon US, LLC $13.20 2022
Biocompatibles, INC. $12.61 2019
Venclose INC. $11.79 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kenneth Otah

$8,280.50

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $441 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/3851/kenneth-otah

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.